Private Advisor Group’s Amicus Therapeutics FOLD Stock Holding History

Private Advisor Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-548	Closed	-$8K	–	2244
2020 Q2	$8K	Buy	+548	New	+$6.68K	﹤0.01%	3023

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Private Advisor Group's FOLD Position: Q3 2020 in Review

Private Advisor Group sold out of Amicus Therapeutics (FOLD) in Q3 2020, closing a stake of 548 shares — an estimated $8K sold.

Private Advisor Group first reported a position in FOLD in Q2 2020 and held it in 1 quarter. The position peaked at $8K in Q2 2020. 251 funds tracked by Wall St. Rank hold FOLD as of Q3 2020.

Private Advisor Group reported no remaining Amicus Therapeutics position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 548 Amicus Therapeutics shares in Q3 2020, an estimated $8K.
Private Advisor Group first reported a position in Amicus Therapeutics in Q2 2020 and held it in 1 quarter.
Private Advisor Group's Amicus Therapeutics position peaked at $8K in Q2 2020.
251 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.